# Increasing Uptake of Long-Acting Injectable Antiretrovirals Among People with HIV

Source: https://welltoldgrants.com/grants/hrsa-22-155-increasing-uptake-of-long-acting-injectable-antiretrovirals/  
Official notice: https://www.grants.gov/search-results-detail/339669

> Health Resources and Services Administration offered grants of up to $1.5 million to nonprofits, colleges and universities, state and local governments and tribes. It expected to make one award worth $1.5 million in total. Applications closed on June 21, 2022.

| Field | Value |
|---|---|
| Opportunity number | HRSA-22-155 |
| Agency | Health Resources and Services Administration |
| Status | Forecast |
| Deadline | June 21, 2022 |
| Award ceiling | $1.5 million |
| Award floor | not stated |
| Expected awards | 1 |
| Total funding | $1.5 million |
| Cost sharing | not required |
| Assistance Listings | 93.899 |

## Who can apply

- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- Others (see text field entitled "Additional Information on Eligibility" for clarification)

Eligible applicants include entities eligible for funding under Parts A-D of Title XXVI of the Public Health Service (PHS) Act, including public and nonprofit private entities, state and local governments, academic institutions; local health departments; nonprofit hospitals and outpatient clinics; colleges and universities; community health centers receiving support under Section 330 of the PHS Act; faith-based and community-based organizations; and Indian Tribes or Tribal organizations with or without federal recognition. Proof of applicant status (e.g., proof of non-profit status) may be requested or required.

## What the grant funds

This notice announces the opportunity to apply for funding under the Increasing Uptake of Long-Acting Injectable Antiretrovirals Among People with HIV cooperative agreement Increasing viral suppression and client retention in care are critical components of meeting the goals of the National HIV/AIDS Strategy (2022-2025) and ending the HIV epidemic. In order to reach these goals, it is imperative for HIV care communities to address health care inequities. With the advent of FDA-approved long-acting injectable (LAI) antiretroviral (ARV) medication formulations, initiatives that promote, facilitate, and evaluate the uptake and ongoing utilization of LAI ARV medication may improve clinical outcomes for people with HIV, especially for minority populations who continue to face disparate health care inequities and stigma. This project is designed to develop protocols, implement them and modify as needed, to increase uptake of LAI ARV medications among people of color with HIV, since LAI ARV medications may offer benefits in addressing health inequities and achieving viral suppression. In addition to alleviating challenges associated with oral medications, ongoing utilization of LAI ARV medications in lieu of oral regimens may potentially reduce HIV-related stigma and enhance protection of health privacy. While there are some unique clinical and social benefits to this injectable drug formulation, some aspects of its distribution, administration requirements, and billing have already hindered uptake and utilization within the Ryan White HIV/AIDS Program (RWHAP). As minority populations have historically experienced significant disparities in accessing care and treatment, including the health literacy and access to health care coverage options necessary to engage in care, developing interventions to increase the uptake of LAI ARV medication formulations will help to proactively address and potentially reduce or prevent disparities minority communities may face in accessing this breakthrough therapy. The main objective of this program is to develop and implement protocols for successful use of LAI ARV medication within clinical practice. This program will fund 1 organization to serve as the Coordination and Evaluation Provider (CEP).

## Questions people ask

### Is HRSA-22-155 still open?

No. It closed on June 21, 2022.

### Who can apply for Increasing Uptake of Long-Acting Injectable Antiretrovirals Among People with HIV?

Health Resources and Services Administration accepted applications from nonprofits, colleges and universities, state and local governments and tribes. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Increasing Uptake of Long-Acting Injectable Antiretrovirals Among People with HIV?

Closed June 21, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

Awards of up to $1.5 million each. About $1.5 million in total for one award.

### Who has won Minority HIV/AIDS Fund (MHAF) grants before?

The largest recipients over five fiscal years were Jsi Research & Training Institute Inc, The Trustees of Columbia University in the City of New York, African-American AIDS Policy and Training Institute. The program made 22 awards worth $26.9 million in that time.